Clinical expansion Metabolic Solutions specializes in stable isotope tracer studies within CLIA- and GLP-compliant labs, offering end-to-end support from study design to regulatory-ready reporting. This positions the company to pursue partnerships with mid-size to large research organizations seeking robust translational data for preclinical and clinical program advancement.

Diverse disease focus Their work spans obesity, protein turnover, liver disease, fibrosis, oncology, and rare diseases, suggesting cross-sell opportunities across multiple therapeutic areas. Engage with researchers and biotechs pursuing metabolic or translational endpoints that can leverage stable isotope methodologies.

Breath test innovations Historical development of Vitamin B12 Breath Test and Pancreatic Breath Test signals a track record of creating simple, functional assays. This could be leveraged to position the company as an innovator in noninvasive metabolic phenotyping for potential collaborators and sponsor-completed study designs.

Growing biotech alignment With 11-50 employees and revenue in the 1M–10M range, Metabolic Solutions sits in a sweet spot for collaborations with small to mid-sized biotech startups and contract research organizations that need specialized assays and regulatory-ready reporting without engaging large CROs.

Digital and global reach A tech stack including LinkedIn Ads, HubSpot, WordPress, Shopify, and Google Cloud indicates active inbound marketing and CRM capabilities. This enables targeted outreach to potential clients in academia and industry, as well as upsell opportunities for additional assays, reporting services, and regulatory-ready deliverables.